CME plans legal challenge to CFTC over approval of perpetual futures

CME Group plans to challenge the U.S. commodities regulator in court after the agency approved perpetual futures, according to comments from outgoing Chief Executive Terrence Duffy reported by CNBC and echoed by Investing.com.

The move sets up a legal dispute between one of the world’s largest derivatives exchange operators and the Commodity Futures Trading Commission, which has oversight of U.S. derivatives markets. Perpetual futures are a type of futures contract that does not have a traditional expiration date, a feature that has made the product popular in parts of the crypto market. CME’s decision to sue suggests the company is prepared to contest both the regulatory approval itself and the broader framework under which the product can be offered.

Duffy’s remarks, as reported by CNBC, came as he said the exchange operator would move ahead with legal action over the agency’s decision. The reports did not provide details on the precise basis of the lawsuit, the timeline for filing, or which specific version of perpetual futures the regulator approved. They also did not say whether the challenge would focus on procedural issues, the substance of the approval, or the regulator’s authority to allow the product in the first place.

The dispute places CME in a familiar position as a major market infrastructure provider closely watched by regulators, exchanges and market participants. CME is a dominant venue for exchange-traded derivatives, and any expansion into new products can have implications for how institutional investors, market makers and other participants access risk exposure. A legal challenge could therefore influence not only the approval at issue, but also how future product launches are handled in the U.S. derivatives market.

The reporting also highlights the ongoing tension between traditional regulated exchanges and newer forms of derivatives that have grown in popularity outside the established futures framework. Perpetual contracts have been especially associated with digital-asset trading, where they are widely used because they allow traders to maintain exposure without rolling contracts forward. The CFTC’s approval appears to have brought that structure closer to the mainstream regulated market, but CME’s response shows that not all major industry players agree on how such products should be introduced or supervised.

For regulators, the case could become an important test of how far the agency can go in permitting innovative derivatives structures while preserving market integrity and investor protection. For CME, the decision to litigate suggests the company sees the approval as more than a routine policy disagreement. It points to a broader contest over where the line should be drawn between established exchange-traded futures and newer contract designs that have emerged in faster-moving markets.

Neither CNBC nor Investing.com reported additional details on court filings, the regulator’s response, or any effect on existing CME products. But the reports make clear that the exchange operator intends to press its objection through the legal system rather than limiting its response to public criticism. That leaves the approval of perpetual futures facing an immediate challenge from one of the most influential names in the listed derivatives industry.